Kerendia · DIN 02531917 · 10mg · tablet
Limited Use — Reason for Use code 700 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 700 required
Write on scriptLU code 700 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 700
Reason for Use code 700
For use as an adjunct to standard-of-care (SOC) therapy in adult patients diagnosed with BOTH chronic kidney disease (CKD) and type 2 diabetes (T2D) to reduce the risk of end-stage kidney disease and a sustained decrease in estimated
glomerular filtration rate (eGFR), and cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in patients who meet the following criteria:
1. 18 years of age or older; AND
2. Diagnosed with CKD with an eGFR level greater than or equal to 25mL/min/1.73 square metres AND an albuminuria level greater than or equal to 30mg/g (or 3mg/mmol); AND
3. Patient is also diagnosed with T2D; AND
4. Finerenone is prescribed in addition to standard-of-care (SOC)* therapy for patients diagnosed with CKD with comorbid T2D; AND
* SOC therapy is defined as maximally tolerated doses of angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy in combination with a sodium-glucose cotransporter-2 (SGLT2) inhibitor unless SGLT2 inhibitors are contraindicated or not tolerated.
5. Patient does not have a diagnosis of chronic heart failure (CHF) with reduced ejection fraction and persistent symptoms meeting New York Heart Association Class II to IV; AND
6. Patient is not using finerenone in combination with another mineralocorticoid receptor antagonist (MRA); AND
7. Finerenone is prescribed in consultation with a nephrologist or other clinician with experience in the diagnosis and management of patients with CKD and T2D.
Discontinuation Criteria:
Patients meeting the initiation criteria and started on finerenone should be discontinued on treatment if the patient's eGFR is less than 15mL/min/1.73 square metres and/or if the urinary albumin-to-creatinine ratio (UACR) has increased from baseline level after starting treatment with finerenone.
Approved Dosage:
Up to 20mg once daily as per the product monograph
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Kerendia · DIN 02531917
Manufacturer: Bayer Inc., Health Care Division; listing date 2024-03-28
Health Canada: Marketed since 2022-11-22 · brand KERENDIA · ATC C03DA05 FINERENONE · form Tablet · route Oral · ingredients FINERENONE 10 MG · company Bayer inc · schedule Prescription
Kerendia: Formulary list price $3.2565/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102100 · Verify on the e-Formulary ↗ (DIN 02531917)
Source record
DIN 02531917: Kerendia
Raw flags: sec12=Y, sec3=Y
Item: 243220001; group id 376; item number 0896; lccId 00386; manufacturer id BAH
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.2565; ministry $3.2565
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02531917
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102100
Shortage status: not checked (no credentials)